Endometrial Cancer Treatment Options

• Surgery — usually a hysterectomy with removal of both fallopian tubes and ovaries — is the primary endometrial cancer treatment for most patients, and lymph nodes may be evaluated at the same time to help guide further care.
• Beyond surgery, doctors may also draw on radiation, drug-based chemotherapy, hormone-blocking agents, molecularly targeted drugs, or immunotherapy for cancer that persists, returns, or has spread.
• The cancer’s stage, the tumor’s grade and cell type, and molecular features such as mismatch repair status all help determine which combination of treatments is recommended.
• Progestin-based hormone therapy is considered for tumors that test positive for hormone receptors, while immunotherapy drugs such as pembrolizumab and dostarlimab have shown the greatest benefit in tumors with mismatch repair deficiency (dMMR).
• Treatment choices also weigh a patient’s age, overall health, and personal priorities, and follow-up care continues well after active treatment ends.

Understanding Endometrial Cancer Treatments

Understanding endometrial cancer treatments begins with recognizing that this disease forms in the endometrium, the inner lining of the uterus. The goal of treatment is to remove or control the cancer, lower the chance it returns, and manage symptoms. A multidisciplinary team — which may include gynecologic oncologists, radiation oncologists, and medical oncologists — works together to recommend the most effective approach for each patient. How common endometrial cancer is, and how outcomes trend over time, are covered in more detail on our other endometrial cancer pages; here, the focus is on the treatments themselves and how doctors choose among them.

Key Endometrial Cancer Treatment Approaches

When people ask what endometrial cancer treatments involve, it helps to know that therapy often combines more than one approach. Standard treatment for endometrial cancer includes surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy, and immunotherapy has become an additional option for select patients. Broadly, these fall into two categories: surgery, which removes the tumor directly, and systemic or localized therapies, which are used alone or together with surgery.

Surgical Interventions

For most patients, surgery comes first and remains the treatment most often used against endometrial cancer. It lets the surgical team take out the visible tumor while also revealing how far the disease has advanced, information that shapes any care that follows.

• Total hysterectomy: removal of the uterus and cervix, performed through the vagina, an abdominal incision, or with a laparoscope.
• Bilateral salpingo-oophorectomy: removal of both fallopian tubes and ovaries, usually done along with the hysterectomy.
• Lymph node dissection: removal of pelvic, and sometimes para-aortic, lymph nodes so they can be checked for cancer cells and help confirm the stage.

Minimally invasive techniques, such as laparoscopic or robotic-assisted surgery, are used in many cases. A large randomized trial comparing laparoscopic surgery with open (laparotomy) surgery found similar recurrence and 5-year survival rates between the two approaches, along with a shorter hospital stay and less pain after laparoscopy.

Radiation and Systemic Therapies

Beyond surgery, several other endometrial cancer treatment options may be used afterward to lower the chance of recurrence, or as the main treatment when surgery is not possible or the cancer has spread.

• Radiation therapy uses high-energy rays to damage cancer cells. External beam radiation therapy directs radiation at the pelvis from a machine outside the body, while brachytherapy places a radioactive source directly inside the vagina for a short time, concentrating the dose near the area where the tumor was.
• Chemotherapy uses drugs, often a platinum agent combined with a taxane, to kill cancer cells or stop them from dividing. It is usually given into a vein and is generally reserved for higher-risk, advanced, or recurrent disease.
• Hormone therapy is most likely to help when a tumor tests positive for estrogen or progesterone receptors. Progestins are the hormonal drugs used most often, and doctors may turn to them when someone is not a good candidate for an operation or radiation, or when the disease is advanced or has come back.
• Targeted therapy aims at specific molecules involved in tumor growth. Options used for advanced or recurrent endometrial cancer include mTOR inhibitors, such as everolimus or ridaforolimus, and the monoclonal antibody bevacizumab.
• Immunotherapy works by helping the immune system recognize and attack cancer cells. Checkpoint inhibitors such as pembrolizumab and dostarlimab are used for advanced or recurrent endometrial cancer, and clinical trials have shown the largest benefit in tumors with mismatch repair deficiency (dMMR), sometimes described as having high microsatellite instability.

Factors Influencing Treatment Decisions

Choosing among these endometrial cancer treatment choices is an individualized process, since no single approach fits everyone. Two broad groups of factors are weighed together: characteristics of the tumor itself, and characteristics of the patient.

Disease Stage and Characteristics

Treatment intensity generally rises with how far the cancer has spread and how abnormal the cells look under a microscope (the tumor’s grade), along with its histologic type and molecular features such as mismatch repair status. Lower-grade, early-stage tumors confined to the uterus are often treated with surgery alone or surgery plus limited radiation, while higher-grade tumors or cancer that has spread beyond the uterus typically call for chemotherapy, more extensive surgery, or systemic therapy in addition to radiation. A full explanation of what each stage means is covered on our endometrial cancer stages page; here, the focus is on how that staging translates into treatment choices.

Patient-Specific Considerations

Beyond the cancer itself, patient-specific factors play a significant role in tailoring endometrial cancer treatment.

• Age and overall health: a patient’s general condition and any other medical conditions can affect how well they tolerate surgery, chemotherapy, or radiation.
• Personal and family plans: because standard surgery removes the uterus and ovaries, patients who have not completed childbearing may want to raise this directly with their care team as part of treatment planning.
• Preferences and quality of life: discussions about potential side effects, recovery time, and long-term impact help patients and their care team choose a plan that reflects the patient’s own priorities.

Emerging Therapies and Clinical Trials

The tools used to treat endometrial cancer continue to evolve as researchers learn more about the disease’s molecular drivers, including the immunotherapy options described above. Clinical trials test new drugs, new combinations, and new ways of using current treatments before they become standard of care. Patients with advanced, recurrent, or molecularly distinct tumors are often good candidates to ask their care team about clinical trial options; the latest research directions for endometrial cancer are covered in more detail elsewhere.

Managing Recovery and Long-Term Care

Once active treatment ends, care shifts to monitoring for recurrence and supporting overall recovery. Follow-up typically includes scheduled physical and pelvic exams, with imaging or blood tests added if there is a specific concern; visits usually become less frequent over time if there is no sign the cancer has returned. Surgery, radiation, and hormonal changes can each bring their own after-effects, which are addressed in detail on our pages about managing treatment side effects and post-treatment care. Support from family, counseling, or a support group can also help during recovery.

Frequently Asked Questions

What is the primary treatment for early-stage endometrial cancer?

For most early-stage endometrial cancer, surgery — a total hysterectomy with removal of both fallopian tubes and ovaries — is the primary treatment. Lymph nodes may also be checked to help confirm the stage. Depending on the tumor’s grade and other features, some patients are offered radiation therapy afterward to lower the chance of recurrence.

How do doctors decide on the best treatment for endometrial cancer?

There is no single “best” treatment for everyone — the choice depends on the cancer’s stage, grade, and molecular features, along with the patient’s age, overall health, and personal preferences. A multidisciplinary team weighs these factors together to build a plan aimed at controlling the cancer while protecting quality of life.

Are there new options for endometrial cancer therapy?

Yes. Immunotherapy drugs such as pembrolizumab and dostarlimab are now used for some patients with advanced or recurrent disease, particularly tumors with mismatch repair deficiency, and targeted therapies continue to be studied in clinical trials. Discussing clinical trial eligibility with your care team is one way to access newer approaches.

Sources

• National Cancer Institute – Endometrial Cancer Treatment (PDQ®)–Patient Version
• National Cancer Institute – Endometrial Cancer Treatment (PDQ®)–Health Professional Version